The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease

Parkinsonism and Related Disorders

Volumn 9, Issue 3, 2003, Pages 131-137

  Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Continuous dopaminergic stimulation; MPTP; Parkinson's disease; Primate

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; ANTIPARKINSON AGENT; BROMOCRIPTINE; CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; NAXAGOLIDE; PERGOLIDE; QUINPIROLE; ROPINIROLE; U 91356A; UNCLASSIFIED DRUG;

BRADYKINESIA; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFECT; DYSKINESIA; HALF LIFE TIME; HUMAN; MOTOR CONTROL; MOTOR DYSFUNCTION; NONHUMAN; OSMOTIC MINIPUMP; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; RECEPTOR SENSITIVITY; REVIEW; RIGIDITY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; PARKINSON DISEASE;

EID: 0037269421     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(02)00115-3     Document Type: Review

References (65)

1. Davis G.C., Williams A.C., Markey S.P., Ebert M.H., Caine E.D., Reichert C.M., Kopin I.J. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatr Res. 1:1979;249-254.
2. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
3. Ballard P.A., Tetrud J.W., Langston J.W. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology. 35:1985;949-956.
4. Carlsson A., Lindquist M., Magnusson T. 3,4-Dihydroxyphenyalanine and 5-hydroxytryptophan as reserpine antagonists. Nature. 180:1957;1200.
5. Jenner P. Experimental models of Parkinson's disease. Ronken E., van Scharrenburg G. Parkinson's disease. 2002;39-50 IOS Press, London.
6. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol. 5:1968;107-110.
7. Gerlach M., Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm. 103:1996;987-1041.
8. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA. 80:1983;4546-4550.
9. Russ H., Mihatsch W., Gerlach M., Riederer P., Przuntek H. Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease? Neurosci Lett. 123:1991;115-118.
10. Stern Y. MPTP-induced parkinsonism. Prog Neurobiol. 34:1990;107-114.
11. Bankiewicz K.S., Plunkett R.J., Jacobowitz D.M., Porrino L., di Porzio U., London W.T., Kopin I.J., Oldfield E.H. The effect of fetal mesencephalon implants on primate MPTP-induced parkinsonism. Histochemical and behavioral studies. J Neurosurg. 72:1990;231-244.
12. Benazzouz A., Boraud T., Feger J., Burbaud P., Bioulac B., Gross C. Alleviation of experimental hemiparkinsonism by high-frequency stimulation of the subthalamic nucleus in primates: a comparison with L-Dopa treatment. Mov Disord. 11:1996;627-632.
13. Guridi J., Herrero M.T., Luquin R., Guillen J., Obeso J.A. Subthalamotomy improves MPTP-induced parkinsonism in monkeys. Stereotact Funct Neurosurg. 62:1994;98-102.
14. Przedborski S., Vila M. MPTP: a review of its mechanisms of neurotoxicity. Clin Neurosci Res. 1:2001;407-418.
15. Nakamura K., Bindokas V.P., Marks J.D., Wright D.A., Frim D.M., Miller R.J., Kang U.J. The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: the role of mitochondrial complex I and reactive oxygen species revisited. Mol Pharmacol. 58:2000;271-278.
16. Lotharius J., O'Malley K.L. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J Biol Chem. 275:2000;38581-38588.
17. Chassain C., Eschalier A., Durif F. Assessment of motor behavior using a video system and a clinical rating scale in parkinsonian monkeys lesioned by MPTP. J Neurosci Meth. 111:2001;9-16.
18. Imbert C., Bezard E., Guitraud S., Boraud T., Gross C.E. Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey. J Neurosci Meth. 96:2000;71-76.
19. Pearce R.K., Jackson M., Smith L., Jenner P., Marsden C.D. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov Disord. 10:1995;731-740.
20. Cenci M.A., Lee C.S., Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci. 10:1998;2694-2706.
21. Boyce S., Rupniak N.M., Steventon M.J., Iversen S.D. Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys. Psychopharmacology (Berlin). 102:1990;21-27.
22. Clarke C.E., Boyce S., Robertson R.G., Sambrook M.A., Crossman A.R. Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci. 90:1989;307-314.
23. Boyce S., Clarke C.E., Luquin R., Peggs D., Robertson R.G., Mitchell I.J., Sambrook M.A., Crossman A.R. Induction of chorea and dystonia in parkinsonian primates. Mov Disord. 5:1990;3-7.
24. Blanchet P.J., Grondin R., Bedard P.J. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. Mov Disord. 11:1996;91-94.
25. Clarke C.E., Boyce S., Sambrook M.A., Stahl S.M., Crossman A.R. Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Naunyn Schmiedebergs Arch Pharmacol. 338:1998;35-38.
26. Clarke C.E., Sambrook M.A., Mitchell I.J., Crossman A.R. Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci. 78:1987;273-280.
27. Kuoppamaki M., Al-Bargouthy G., Jackson M., Smith L., Zeng B.Y., Quinn N., Jenner P. Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with L-dopa. Mov Disord. 17(6):2002;1312-1317.
28. Lees A.J., Haddad S., Shaw K.M., Kohout L.J., Stern G.M. Bromocriptine in parkinsonism. A long-term study. Arch Neurol. 35:1978;503-505.
29. Lees A.J., Stern G.M. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 44:1981;1020-1023.
30. Rascol A., Guiraud B., Montastruc J.L., David J., Clanet M. Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry. 42:1979;143-150.
31. 3H]spiperone binding. Brain Res. 379:1986;294-299.
32. Falardeau P., Bouchard S., Bedard P.J., Boucher R., Di Paolo T. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys. Eur J Pharmacol. 150:1988;59-66.
33. Pearce R.K., Banerji T., Jenner P., Marsden C.D. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord. 13:1998;234-241.
34. Bedard P.J., Mancilla B.G., Blanchette P., Gagnon C., Di Paolo T. Levodopa-induced dyskinesia: facts and fancy. What does the MPTP monkey model tell us? Can J Neurol Sci. 19:1992;134-137.
35. Gomez-Mancilla B., Bedard P.J. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys. Exp Neurol. 117:1992;185-188.
36. Luquin M.R., Laguna J., Obeso J.A. Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys. Ann Neurol. 31:1992;551-554.
37. Obeso J.A., Olanow C.W., Nutt J.G. Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23:2000;S2-S7.
38. Olanow W., Schapira A.H., Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci. 23:2000;S117-S126.
39. Nutt J.G., Obeso J.A., Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci. 23:2000;S109-S115.
40. Olanow C.W., Obeso J.A. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology. 55:2000;S72-S77. discussion S78-81.
41. Stocchi F. Continuous dopaminergic stimulation in parkinson's disease treatment. Focus Parkinson's Dis. 10:1998;60-63.
42. Blanchet P.J., Calon F., Martel J.C., Bedard P.J., Di Paolo T., Walters R.R., Piercey M.F. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther. 272:1995;854-859.
43. Morissette M., Goulet M., Soghomonian J.J., Blanchet P.J., Calon F., Bedard P.J., Di Paolo T. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. Brain Res Mol Brain Res. 49:1997;55-62.
44. Grondin R., Goulet M., Di Paolo T., Bedard P.J. Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates. Brain Res. 735:1996;298-306.
45. Hadj Tahar A., Gregoire L., Bangassoro E., Bedard P.J. Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys. Clin Neuropharmacol. 23:2000;195-202.
46. Maratos E.C., Jackson M.J., Pearce R.K., Jenner P. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus). Mov Disord. 16:2001;631-641.
47. Korczyn A.D., Brunt E.R., Larsen J.P., Nagy Z., Poewe W.H., Ruggieri S. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. Neurology. 53:1999;364-370.
48. Rascol O., Brooks D.J., Brunt E.R., Korczyn A.D., Poewe W.H., Stocchi F. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord. 13:1998;39-45.
49. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med. 342:2000;1484-1491.
50. Rinne U.K., Bracco F., Chouza C., Dupont E., Gershanik O., Marti Masso J.F., Montastruc J.L., Marsden C.D. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs. 55:(Suppl 1):1998;23-30.
51. Rinne U.K., Bracco F., Chouza C., Dupont E., Gershanik O., Marti Masso J.F., Montastruc J.L., Marsden C.D., Dubini A., Orlando N., Grimaldi R. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology. 48:1997;363-368.
52. Agid Y., Ahlskog E., Albanese A., Calne D., Chase T., De Yebenes J., Factor S., Fahn S., Gershanik O., Goetz C., Koller W., Kurth M., Lang A., Lees A., Lewitt P., Marsden D., Melamed E., Michel P.P., Mizuno Y., Obeso J., Oertel W., et al. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov Disord. 14:1999;911-913.
53. Olanow C.W., Watts R.L., Koller W.C. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 56:2001;S1-S88.
54. Smith L.A., Gordin A., Jenner P., Marsden C.D. Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets. Mov Disord. 12:1997;935-945.
55. Ruottinen H.M., Rinne U.K. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol. 19:1996;283-296.
56. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol. 42:1997;747-755.
57. Rinne U.K., Larsen J.P., Siden A., Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology. 51:1998;1309-1314.
58. Smith L.A., Jackson M.J., Hansard M., Maratos E., Jenner P. Effect of pulsatile administration of L-dopa on dyskinesia induction in drug naïve MPTP-treated common marmosets: effect of dose, frequency of administration and brain exposure. Mov Disord. 2003.
59. Jenner P, Al-Barghouthy G, Smith L, Kuoppamaki M, Jackson M, Rose S, Olanow CW. Initiation of entacapone with L-DOPA further improves antiparkinsonian activity and avoids dyskinesia in the MPTP primate model of Parkinson's disease. Poster presented at the 54th. Annual Meeting of the American Academy of Neurology 2002, Denver, Colorado, USA. Poster P05.096.
60. Vingerhoets F.J., Snow B.J., Tetrud J.W., Langston J.W., Schulzer M., Calne D.B. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol. 36:1994;765-770.
61. Bezard E., Imbert C., Gross C.E. Experimental models of Parkinson's disease: from the static to the dynamic. Rev Neurosci. 9:1998;71-90.
62. Moratalla R., Quinn B., DeLanney L.E., Irwin I., Langston J.W., Graybiel A.M. Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA. 89:1992;3859-3863.
63. Pifl C., Schingnitz G., Hornykiewicz O. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease. Neurosci Lett. 92:1988;228-233.
64. Elsworth J.D., Deutch A.Y., Redmond D.E. Jr, Taylor J.R., Sladek J.R. Jr, Roth R.H. Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates: biochemical changes in striatal regions. Neuroscience. 33:1989;323-331.
65. Snow B.J., Vingerhoets F.J., Langston J.W., Tetrud J.W., Sossi V., Calne D.B. Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J Neurol Neurosurg Psychiatry. 68:2000;313-316.